Stockscreener 앱 받기
103.10
1.07%
1.09
전일 마감가:
$102.01
열려 있는:
$102.09
하루 거래량:
682.80K
Relative Volume:
0.92
시가총액:
$6.17B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-63.95
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
+2.62%
1개월 성능:
+14.00%
6개월 성능:
+58.27%
1년 성능:
+103.35%
1일 변동 폭
$100.83
$103.70
1주일 범위
$98.25
$103.70
52주 변동 폭
$36.88
$105.74
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
103.10 | 6.11B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 14% Upside Potential - DirectorsTalk Interviews
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Yahoo Finance
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
Mirum Pharmaceuticals (MIRM) Price Target Increased by 10.50% to 116.99 - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $940,856.40 in Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock - MarketBeat
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock By Investing.com - Investing.com South Africa
Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock - Investing.com Australia
Mirum Pharma president & COO sells $271k in stock - Investing.com
Mirum Pharma president & COO sells $271k in stock By Investing.com - Investing.com India
Mirum Pharma CEO Peetz sells $941k in shares By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (MIRM): Investor Outlook on a Biotech with a 10.5% Upside Potential - DirectorsTalk Interviews
Y Intercept Hong Kong Ltd Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum doubles down on diversified rare disease strategy - PharmaVoice
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals stock hits all-time high at 103.94 USD - Investing.com
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Atle Fund Management AB - MarketBeat
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - The Motley Fool
EV Market: Is Mirum Pharmaceuticals Inc impacted by rising rates2025 Winners & Losers & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug PreEarnings: Is Tronox Holdings plc impacted by rising ratesIndex Update & Trade Opportunity Analysis - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $123.00 at Morgan Stanley - MarketBeat
Chronic hepatitis D market set for steady growth as pipeline inches forward - The Pharma Letter
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? - Finviz
11 Best Stocks to Buy for Investment - Insider Monkey
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
HC Wainwright Has Negative Outlook of MIRM FY2027 Earnings - MarketBeat
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com - Investing.com UK
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m - Investing.com
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mirum Pharmaceuticals Inc 주식 (MIRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Radovich Peter | PRESIDENT AND COO |
Feb 02 '26 |
Sale |
103.30 |
2,631 |
271,792 |
20,655 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Feb 02 '26 |
Sale |
103.30 |
9,108 |
940,888 |
160,294 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Feb 02 '26 |
Sale |
103.30 |
968 |
99,998 |
4,503 |
1.12%
0.87%
자본화:
|
볼륨(24시간):